The effects of phencyclidine on the NMDA receptor-neuregulin1 signalling complex: implications for schizophrenia

苯环己哌啶对 NMDA 受体-神经调节蛋白 1 信号复合物的影响：对精神分裂症的影响

• 批准号: nhmrc : 573426
• 负责人: A/Pr Kelly Newell
• 金额: $ 28.93万
• 依托单位: University of Wollongong
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2009
• 资助国家: 澳大利亚
• 起止时间: 2009-01-01 至 2012-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/effects-phencyclidine-nmda-implications-schizophrenia/101409
• 关键词: effects; phencyclidine; NMDA; receptor; neuregulin1

Phencyclidine is the best known pharmacological agent that can induce schizophrenia-like symptoms in humans and animals. Recent research has strongly suggested that neuregulin1 and ErbB4 signalling are involved in schizophrenia pathology. This study will be the first to determine whether neuregulin1 is altered by phencyclidine, which will further our knowledge by re-evaluating the causal role of neuregulin1 in schizophrenia.

苯环利定是最著名的能在人类和动物中诱发精神分裂症样症状的药物。最近的研究强烈表明，神经调节蛋白1和ErbB4信号通路参与了精神分裂症的病理过程。这项研究将首次确定神经调节蛋白1是否被苯环利定改变，这将通过重新评估神经调节蛋白1在精神分裂症中的因果作用进一步加深我们的认识。